// Auto-generated - do not edit
export const substanceName = "Moclobemide";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Moclobemide.md","displayName":"DrugBank","size":20836},{"id":"protestkit","fileName":"PROTESTKIT - Moclobemide.json","displayName":"Protest Kit","size":3029},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Moclobemide.md","displayName":"TripSit Factsheets","size":494},{"id":"wikipedia","fileName":"WIKIPEDIA - Moclobemide.md","displayName":"Wikipedia","size":30562}];
export const contents: Record<string, string> = {
  "drugbank": `# Moclobemide
*Source: https://go.drugbank.com/drugs/DB01171*

## Overview

### Description

This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.

### Background

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs).  Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants
1
.

### Indication

For the treatment of major depressive disorder and bipolar disorder
1
.

### Pharmacodynamics

A selective, reversible inhibitor of monoamine oxidase (MAO) which increases the
1
. Besides its presence in sympathetic nerves, there is an abundant evidence that MAO-A is localized in noradrenergic neurons in the locus coeruleus and MAO-B is closely associated with serotonergic neurons of the raphe nucleus
1
.

### Mechanism of Action

Amine oxidase [flavin-containing] A
Antagonist
Inhibitor

### Absorption

Well absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first-pass metabolism reduces bioavailability to about 56% following administration of one dose, but increases to 90% with steady-state dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 0.3 - 1 hours following oral administration with a terminal half-life of 1.6h
4
.

### Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.
Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6
1
.
Hover over products below to view reaction partners
Moclobemide
Moclobemide M5
Moclobemide M6
Moclobemide M3
Moclobemide M1
Moclobemide M11
+
Moclobemide M13
+
Moclobemide M14
+
Moclobemide M15
+
Moclobemide M16
+
Moclobemide M18
Moclobemide M8
Moclobemide M4
Moclobemide M2
+
Moclobemide M7
Moclobemide M9

### Half-life

1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted

### Toxicity

LD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures
3
. The effects of moclobemide alone in overdose are negligible, even with high volume ingestion.  However, moclobemide overdose with a serotonergic agent (even in small, therapeutic doses) can cause severe serotonin toxicity. The elimination half-life is prolonged by two to four times in overdose, compared with that found in healthy volunteers given therapeutic doses
3
.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Moclobemide is combined with 1,2-Benzodiazepine.
Abaloparatide
Moclobemide may increase the orthostatic hypotensive activities of Abaloparatide.
Abatacept
The metabolism of Moclobemide can be increased when combined with Abatacept.
Abciximab
The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Abciximab.
Abiraterone
The metabolism of Moclobemide can be decreased when combined with Abiraterone.

### Food Interactions

Avoid excessive or chronic alcohol consumption.
Avoid tyramine-containing foods and supplements. Avoid excess consumption (<100mg) of tyramine. Food that contains tyramine includes yogurt, aged cheese, ripe bananas, wine, and sourdough bread.
Take after a meal.

## Chemical Information

**DrugBank ID:** DB01171

**Synonyms:** 4-Chlor-N-(2-morpholinoethyl)benzamid
Moclobemid
Moclobemida
Moclobemide
Moclobemidum
p-Chloro-N-(2-morpholinoethyl)benzamide

**Chemical Formula:** C
13
H
17
ClN
2
O
2

**SMILES:** ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1

**Weight:** Average: 268.739
Monoisotopic: 268.097855505

**IUPAC Name:** 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

0

### Phase 2

2

### Phase 3

2

### Phase 4

1

### Therapeutic Categories

Antidepressive Agents Indicated for
Depression
Monoamine Oxidase
Inhibitors

### Summary

Moclobemide
is a monoamine oxidase inhibitor used in the treatment of major depressive disorder and bipolar disorder.

### Brand Names

Manerix

### Generic Name

Moclobemide

### DrugBank Accession Number

DB01171

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Moclobemide (DB01171)
×
Close

### External IDs

GNF-PF-695
RO 11-1163/000
RO-11-1163/000
RO-111163000

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Major depressive disorder
••••••••••••
Create Account
Create Account

### Mechanism of action

The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms
1
,
2
.
Target
Actions
Organism
A
Amine oxidase [flavin-containing] A
antagonist
inhibitor
Humans
U
Monoamine oxidase
antagonist
Humans
U
Amine oxidase [flavin-containing] B
antagonist
Humans

### Volume of distribution

1-1.5 L/Kg
4

### Protein binding

Approximately 50% (primarily to albumin)
4

### Route of elimination

Moclobemide is almost completely renally excreted
4
.

### Clearance

Clearance of 30-78  L/h
4
, mainly excreted in urine.

### International/Other Brands

Aurorix

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Manerix
Tablet
300 mg
Oral
Bausch Health, Canada Inc.
1995-12-31
Not applicable
Canada
Manerix
Tablet
150 mg
Oral
Bausch Health, Canada Inc.
1992-12-31
Not applicable
Canada
Manerix Tab 100mg
Tablet
100 mg / tab
Oral
Hoffmann La Roche
1992-12-31
1997-12-04
Canada
Moclobemide
Tablet
300 mg
Oral
Aa Pharma Inc
1999-07-14
Not applicable
Canada
Moclobemide
Tablet
150 mg
Oral
Aa Pharma Inc
1997-09-18
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Dom-moclobemide Tablets 150mg
Tablet
150 mg
Oral
Dominion Pharmacal
2001-02-15
2016-10-26
Canada
Dom-moclobemide Tablets 300mg
Tablet
300 mg
Oral
Dominion Pharmacal
2001-02-15
2016-10-26
Canada
Nu-moclobemide
Tablet
150 mg
Oral
Nu Pharm Inc
1998-07-28
2012-09-04
Canada
Nu-moclobemide
Tablet
100 mg
Oral
Nu Pharm Inc
1998-07-29
2012-09-04
Canada
PMS-moclobemide
Tablet
300 mg
Oral
Pharmascience Inc
2001-01-08
Not applicable
Canada

### ATC Codes

N06AG02 — Moclobemide
N06AG — Monoamine oxidase A inhibitors
N06A — ANTIDEPRESSANTS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Acids, Carbocyclic
Agents that produce hypertension
Agents that reduce seizure threshold
Amides
Antidepressive Agents
Antidepressive Agents Indicated for Depression
Benzamides and benzamide derivatives
Benzene Derivatives
Benzoates
Central Nervous System Agents
Central Nervous System Depressants
Chlorobenzoates
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2C19 inhibitors (strength unknown)
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors (strength unknown)
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Enzyme Inhibitors
Monoamine Oxidase A Inhibitors
Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates
Monoamine Oxidase Inhibitors
Nervous System
Psychoanaleptics
Psychotropic Drugs
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Serotonin Agents
Serotonin Modulators

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
4-halobenzoic acids and derivatives
Alternative Parents
Benzamides
/
Benzoyl derivatives
/
Chlorobenzenes
/
Morpholines
/
Aryl chlorides
/
Trialkylamines
/
Secondary carboxylic acid amides
/
Amino acids and derivatives
/
Oxacyclic compounds
/
Dialkyl ethers
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
show 5 more
Substituents
4-halobenzoic acid or derivatives
/
Amine
/
Amino acid or derivatives
/
Aromatic heteromonocyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzamide
/
Benzoyl
/
Carboxamide group
/
Carboxylic acid derivative
/
Chlorobenzene
/
Dialkyl ether
/
Ether
/
Halobenzene
/
Hydrocarbon derivative
/
Morpholine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Oxazinane
/
Secondary carboxylic acid amide
/
Tertiary aliphatic amine
/
Tertiary amine
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, monochlorobenzenes, morpholines (
CHEBI:83531
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Benzoic acids and derivatives

### Direct Parent

4-halobenzoic acids and derivatives

### Alternative Parents

Benzamides
/
Benzoyl derivatives
/
Chlorobenzenes
/
Morpholines
/
Aryl chlorides
/
Trialkylamines
/
Secondary carboxylic acid amides
/
Amino acids and derivatives
/
Oxacyclic compounds
/
Dialkyl ethers
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Organic oxides
/
Hydrocarbon derivatives
show 5 more

### Substituents

4-halobenzoic acid or derivatives
/
Amine
/
Amino acid or derivatives
/
Aromatic heteromonocyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Benzamide
/
Benzoyl
/
Carboxamide group
/
Carboxylic acid derivative
/
Chlorobenzene
/
Dialkyl ether
/
Ether
/
Halobenzene
/
Hydrocarbon derivative
/
Morpholine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organoheterocyclic compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Oxacycle
/
Oxazinane
/
Secondary carboxylic acid amide
/
Tertiary aliphatic amine
/
Tertiary amine
show 21 more

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

benzamides, monochlorobenzenes, morpholines (
CHEBI:83531
)

### Affected organisms

Humans and other mammals

### UNII

PJ0Y7AZB63

### CAS number

71320-77-9

### InChI Key

YHXISWVBGDMDLQ-UHFFFAOYSA-N

### InChI

InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)

### General References

Bonnet U: Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 Spring;9(1):97-140. doi: 10.1111/j.1527-3458.2003.tb00245.x. [
Article
]
Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K: Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7. doi: 10.1016/0009-9236(95)90230-9. [
Article
]
Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ: Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. 2003 Oct;56(4):441-50. [
Article
]
Monamine Oxidase Inhibitors [
Link
]
Citalopram [
Link
]

### External Links

Human Metabolome Database
HMDB0015302
KEGG Drug
D02561
PubChem Compound
4235
PubChem Substance
46504667
ChemSpider
4087
BindingDB
15613
RxNav
30121
ChEBI
83531
ChEMBL
CHEMBL86304
ZINC
ZINC000019606670
Therapeutic Targets Database
DAP000576
PharmGKB
PA452615
Wikipedia
Moclobemide

### Human Metabolome Database

HMDB0015302

### KEGG Drug

D02561

### PubChem Compound

4235

### PubChem Substance

46504667

### ChemSpider

4087

### BindingDB

15613

### RxNav

30121

### ChEBI

83531

### ChEMBL

CHEMBL86304

### ZINC

ZINC000019606670

### Therapeutic Targets Database

DAP000576

### PharmGKB

PA452615

### Wikipedia

Moclobemide

### Dosage Forms

Form
Route
Strength
Solution
Oral
100.000 mg
Tablet
Oral
Tablet, coated
Oral
150 mg
Tablet, film coated
Oral
Tablet
Oral
100 mg / tab
Tablet, film coated
Oral
150 MG
Tablet, film coated
Oral
300 MG
Tablet
Oral
150 mg
Tablet
Oral
150 mg / tab
Tablet
Oral
300 mg / tab
Tablet
Oral
100 mg
Tablet
Oral
300 mg

### Prices

Unit description
Cost
Unit
Manerix 300 mg Tablet
1.34USD
tablet
Apo-Moclobemide 300 mg Tablet
0.75USD
tablet
Novo-Moclobemide 300 mg Tablet
0.75USD
tablet
Pms-Moclobemide 300 mg Tablet
0.75USD
tablet
Manerix 150 mg Tablet
0.68USD
tablet
Apo-Moclobemide 150 mg Tablet
0.38USD
tablet
Novo-Moclobemide 150 mg Tablet
0.38USD
tablet
Pms-Moclobemide 150 mg Tablet
0.38USD
tablet
Apo-Moclobemide 100 mg Tablet
0.26USD
tablet
Novo-Moclobemide 100 mg Tablet
0.26USD
tablet
Nu-Moclobemide 100 mg Tablet
0.26USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
132
[L1357]
boiling point (°C)
377
[L1357]
water solubility
3.52e-04
[L1357]
logP
10.6
[L1357]
pKa
10.6 (ethanol-air)
[L1357]

### Predicted Properties

Property
Value
Source
Water Solubility
1.12 mg/mL
ALOGPS
logP
1.56
ALOGPS
logP
1.45
Chemaxon
logS
-2.4
ALOGPS
pKa (Strongest Acidic)
14.73
Chemaxon
pKa (Strongest Basic)
6.02
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
41.57 Å
2
Chemaxon
Rotatable Bond Count
4
Chemaxon
Refractivity
71.93 m
3
·mol
-1
Chemaxon
Polarizability
28.21 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9838
Blood Brain Barrier
+
0.9691
Caco-2 permeable
-
0.5602
P-glycoprotein substrate
Substrate
0.6652
P-glycoprotein inhibitor I
Inhibitor
0.6892
P-glycoprotein inhibitor II
Non-inhibitor
0.8637
Renal organic cation transporter
Non-inhibitor
0.5691
CYP450 2C9 substrate
Non-substrate
0.8538
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.5723
CYP450 1A2 substrate
Non-inhibitor
0.9138
CYP450 2C9 inhibitor
Non-inhibitor
0.8989
CYP450 2D6 inhibitor
Non-inhibitor
0.8081
CYP450 2C19 inhibitor
Inhibitor
0.8024
CYP450 3A4 inhibitor
Non-inhibitor
0.9384
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.5956
Ames test
Non AMES toxic
0.6867
Carcinogenicity
Non-carcinogens
0.8727
Biodegradation
Not ready biodegradable
0.9844
Rat acute toxicity
2.6098 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.7135
hERG inhibition (predictor II)
Inhibitor
0.5646
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0fmr-7930000000-f5021f0bbc3af0c7125e
Mass Spectrum (Electron Ionization)
MS
splash10-0udi-2900000000-c3230d46878446405991
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-3436435ae42cfbae36f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-014i-0090000000-ebaa843d45c4c64c1d3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-00lr-0970000000-ab2fbe8b1feae9ff3141
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-e3243f45e1029a4c0e71
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-927950435244f3ac04e4
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-6fe640038cbc911e2bae
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-26e37ce9ba0b814b7409
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-014i-0090000000-07e0ca3dba489a2810ec
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-00lr-0980000000-70103607e1e68c966be9
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-ac7d3f04849dde0da3d2
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001r-0900000000-6634fb6b07312ce02ee6
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-c43f4a856e6d225766ef
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-000i-0900000000-1231bd387729155af4ab
LC-MS/MS Spectrum - LC-ESI-ITFT , positive
LC-MS/MS
splash10-001i-0900000000-a885de4ee2be84e3748d
MS/MS Spectrum - , positive
LC-MS/MS
splash10-00lr-0950000000-2942178c074461702181
MS/MS Spectrum - , positive
LC-MS/MS
splash10-0019-2900000000-bf1e7c693c96e9a69966
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-389657d559087257f416
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-d36276d4afe418710c2e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-03dr-1910000000-a812973a60da6c02988e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00pl-8950000000-c06cdf015556b47f7f4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-06s9-0910000000-d55581dc79ab5f356585
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-001i-9220000000-0afc47571144e22a20a0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-389657d559087257f416
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-0290000000-d36276d4afe418710c2e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-03dr-1910000000-a812973a60da6c02988e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-00pl-8950000000-c06cdf015556b47f7f4b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-06s9-0910000000-d55581dc79ab5f356585
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-001i-9220000000-0afc47571144e22a20a0
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
166.3818777
predicted
DarkChem Lite v0.1.0
[M-H]-
156.05547
predicted
DeepCCS 1.0 (2019)
[M-H]-
166.3818777
predicted
DarkChem Lite v0.1.0
[M-H]-
156.05547
predicted
DeepCCS 1.0 (2019)
[M+H]+
166.8811777
predicted
DarkChem Lite v0.1.0
[M+H]+
158.44276
predicted
DeepCCS 1.0 (2019)
[M+H]+
166.8811777
predicted
DarkChem Lite v0.1.0
[M+H]+
158.44276
predicted
DeepCCS 1.0 (2019)
[M+Na]+
166.6011777
predicted
DarkChem Lite v0.1.0
[M+Na]+
164.5066
predicted
DeepCCS 1.0 (2019)
[M+Na]+
166.6011777
predicted
DarkChem Lite v0.1.0
[M+Na]+
164.5066
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inhibitor

### General Function

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924). Preferentially degrades benzylamine and phenylethylamine (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924)

### Specific Function

electron transfer activity

### Gene Name

MAOB

### Uniprot ID

P27338

### Uniprot Name

Amine oxidase [flavin-containing] B

### Molecular Weight

58762.475 Da

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/moclobemide",
  "experiencesUrl": "https://www.erowid.org/experiences/subs/exp_Moclobemide.shtml",
  "name": "Moclobemide",
  "aliases": [],
  "aliasesStr": "",
  "summary": "A reversible MAOI which is prescribed to treat depression and anxiety. Its reversibility and short-acting length of effects often means it is used in \\"pharmahuasca\\" preparations.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "150mg"
        },
        {
          "name": "Common",
          "value": "300mg"
        },
        {
          "name": "Strong",
          "value": "600mg."
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.5 - 1.5 hours"
        },
        {
          "name": "Duration",
          "value": "2.0 - 6.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Caution"
    },
    {
      "name": "2C-x",
      "status": "Caution"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Dangerous"
    },
    {
      "name": "Alcohol",
      "status": "Unsafe"
    },
    {
      "name": "Amphetamines",
      "status": "Dangerous"
    },
    {
      "name": "Benzos",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Cocaine",
      "status": "Dangerous"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "DOx",
      "status": "Caution"
    },
    {
      "name": "DXM",
      "status": "Dangerous"
    },
    {
      "name": "GHB/GBL",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MDMA",
      "status": "Dangerous"
    },
    {
      "name": "MMC class",
      "status": "Unsafe"
    },
    {
      "name": "MXE",
      "status": "Unsafe"
    },
    {
      "name": "Mescaline",
      "status": "Caution"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "NBOMes",
      "status": "Caution"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Opioids",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Dangerous"
    },
    {
      "name": "SSRIs",
      "status": "Dangerous"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": null,
  "categorized_effects": {
    "Physical effects": [],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Moclobemide
*Source: TripSit Factsheets (tripsit.me)*

## Summary

A reversible MAOI which is prescribed to treat depressive and anxiety disorders. Due to its reversibility and short-acting effects it is often used in "pharmahuasca" preparations.

## Dosage

### Oral
- **Common:** 300mg
- **Light:** 150mg
- **Strong:** 600mg.

## Duration
- **Onset:** 30-90 minutes
- **Duration:** 2-6 hours

## External Links
- [experiences](https://www.erowid.org/experiences/subs/exp_Moclobemide.shtml)
`,
  "wikipedia": `# Moclobemide
*Source: https://en.wikipedia.org/wiki/Moclobemide*

Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the United Kingdom and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.
No significant rise in blood pressure occurs when moclobemide is combined with amines such as tyramine-containing foods or pressor amine drugs, unlike with the older irreversible and non-selective monoamine oxidase inhibitors (MAOIs), which cause a severe rise in blood pressure with such combination. Due to the lack of anticholinergic, cardiovascular, cognitive and psychomotor impairments moclobemide is advantageous in the elderly as well as those with cardiovascular disease.
Moclobemide was first introduced for medical use in 1989.

## Medical uses

### Psychiatric disorders

Reversible selective MAOIs such as moclobemide are underprescribed due to the misconception that the side effect profiles are analogous to that of the irreversible and non-selective MAOIs. MAOIs such as moclobemide are reported to have a relatively fast onset of action compared to other antidepressant drug classes, and have good long-term tolerability in terms of side effects.
Tolerance does not seem to occur; research has found that moclobemide retains its beneficial therapeutic properties in depression for at least a year.

Unipolar depression – Moclobemide has demonstrated effectiveness and efficacy in the treatment and management of major depressive disorder, with both endogenous and non-endogenous depression responding; in addition moclobemide has a fast onset of action compared to other antidepressants and is significantly more tolerable than the tricyclic antidepressants. Due to a good safety profile and low incidence of side effects moclobemide is likely to have a high level of acceptability by individuals suffering from depression. Higher doses (>450 mg/day) may be more effective in severe depression, while patients treated with a lower dose tend to respond less well than those treated with tricyclic antidepressants.
Psychotic depression, unipolar endogenous depression, melancholic depression, retarded depression, agitated depression and neurotic depression all respond to moclobemide, as does atypical depression. Unipolar endogenous depression is reported to have the best response to moclobemide therapy. Individuals suffering from depression who are given moclobemide are twice as likely to improve on moclobemide than on placebo. A concern of antidepressant adverse effects is sexual dysfunction; however, moclobemide has been found to actually increase libido and  improve impaired erection, ejaculation and orgasm. Cardiovascular toxicity is a concern with antidepressants such as tricyclic antidepressants as well as the irreversible MAOIs; when cardiovascular toxicity is a concern, SSRIs or the reversible MAOIs such as moclobemide are an option as they lack or have a significantly reduced level of cardiovascular toxicity in terms of adverse effect as well as in overdose.
The effectiveness of moclobemide in agitated depression is equivalent to that of imipramine and sedative antidepressants such as amitriptyline, mianserin and maprotiline. The therapeutic response in agitated depressive individuals is similar to that seen in non-agitated depression; however, a past history of use of antidepressants reduces the chance of successful therapeutic response. The addition of a benzodiazepine to moclobemide therapy has not been found to be of benefit in this population group. Moclobemide has better tolerability compared to TCAs.
Dysthymia – moclobemide has been found to be effective in the treatment and management of this depressive disorder.
Social phobia – Moclobemide has been found to be effective for the treatment of social anxiety disorder in both short and long-term placebo controlled clinical trials. Moclobemide is effective but not as effective as the irreversible MAOIs in the treatment of social phobia. Maximal benefits can take 8–12 weeks to manifest. There is a high risk of treatment failure if there is co-morbid alcohol use disorder, however. The Australian Medicines Handbook lists social phobia as an accepted but not a licensed indication. The use of moclobemide in the treatment of social anxiety disorder has given mixed results with a tendency of response at higher doses (>300 mg/d) compared with placebo.
Smoking cessation – Moclobemide has been tested in heavy dependent smokers against placebo based on the theory that tobacco smoking could be a form of self-medicating of major depression, and moclobemide could therefore help increase abstinence rates due to moclobemide mimicking the MAO-A inhibiting effects of tobacco smoke. A 2023 Cochrane review found only one 1995 trial studying the effects of moclobemide on smoking cessation, it was administered for 3 months and then stopped; at 6 months follow-up it was found those who had taken moclobemide for 3 months had a much higher successful quit rate than those in the placebo group. However, at 12-month follow-up the difference between the placebo group and the moclobemide group was no longer significant.
Panic disorder – moclobemide is useful in the treatment and management of panic disorder. Panic disorder is mentioned as an accepted but unlicensed indication in the Australian Medicines Handbook.
ADHD – Two small studies assessing the benefit of moclobemide in people with attention deficit disorder found that moclobemide produced favourable results.
Fibromyalgia – moclobemide has been found to improve pain and functioning in this group of people.
Similar to other MAOIs, reversible MAOIs such as moclobemide may also be effective in a range of other psychiatric disorders. Menopausal flushing may also respond to moclobemide.
In efficacy studies for the treatment of major depressive disorder, moclobemide has been found to be significantly more effective than placebo, as effective as the tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), and somewhat less effective than the older, irreversible MAOIs phenelzine and tranylcypromine. In terms of tolerability, however, moclobemide was found to be comparable to the SSRIs and better tolerated than the TCAs and older MAOIs. There is some evidence that moclobemide on its own or in combination with other antidepressants such as SSRIs is also effective for treatment resistant depression and that the combination can be administered without the development of serotonin syndrome; however, further research is needed before such a combination can be recommended. Follow-up studies show that ongoing use of antidepressants leads to continuing improvement in depression over time; and also have demonstrated that moclobemide retains its therapeutic efficacy as an antidepressant for at least a year. This long-term efficacy is equivalent to that seen with other antidepressant classes.
People on irreversible MAOIs have to discontinue these antidepressants two weeks before general anesthesia, however, the use of moclobemide, due to its reversible nature, would allow such patients to possibly continue antidepressant therapy.
A dexamethasone suppression test (DST) and plasma and urine methoxyhydroxyphenylglycol (MHPG) test can be used to estimate who is likely to respond to moclobemide antidepressant therapy.

### Combination with psychedelics

Moclobemide has been used as a component of "pharmahuasca" (pharmaceutical ayahuasca), in which the serotonergic psychedelic dimethyltryptamine (DMT) is combined with a synthetically produced or pharmaceutical monoamine oxidase inhibitor (MAOI) rather than with naturally sourced harmala alkaloids. This inhibits the metabolism of DMT and allows it to become orally active and to have a much longer duration than it would otherwise.

### Special populations

#### Pregnancy and lactation

The doses of moclobemide in breast milk are very low (0.06% of moclobemide being recovered in breast milk) and therefore it has been concluded that moclobemide is unlikely to have any adverse effect on a suckling baby.

#### Children

Use in children is not recommended as there is insufficient data to assess safety and efficacy in these patients.

#### Elderly

Reversible MAOIs such as moclobemide may have advantages in the treatment of depression associated with Alzheimer's disease due to its effect on noradrenaline. Cognitive impairments have been found to improve in people with dementia when depression is treated with moclobemide. Due to its superior safety profile, moclobemide has been recommended as a first line agent for the treatment of depression in the elderly. Due to the side effect profile of moclobemide, it may be a better option for this sub group of people than other antidepressants. Research has found evidence that moclobemide may be able to counter anti-cholinergic (Scopolamine) induced cognitive impairments thus making moclobemide a good choice in the depression in the elderly and those with dementia.

## Contraindications

Avoid use in:

Confusional states
Phaeochromocytoma
and caution is recommended in:

Agitated/excited patients
Thyrotoxicosis

## Adverse effects

The incidence of adverse events is not correlated with age; however, adverse events occur more often in females than in males. Moclobemide is regarded as a generally safe antidepressant and due to its favorable side effect profile, it can be considered a first-line therapeutic antidepressant. The rate of incidence of side effects of moclobemide is low, with insomnia, headache and dizziness being the most commonly reported side effects in the initial stages of therapy with moclobemide. Moclobemide, even at high doses of 600 mg, does not impair the ability to drive a motor vehicle. The tolerability of moclobemide is similar in women and men and it is also well tolerated in the elderly. Moclobemide has been found to be superior to tricyclic and irreversible MAOI antidepressants in terms of side effects, as it does not cause anticholinergic, sedative or cardiovascular adverse effects.
Unlike the irreversible MAOIs there is no evidence of liver toxicity with moclobemide. Moclobemide has a similar efficacy profile compared to other antidepressants while being superior to the classic MAOIs and the tricyclics in terms of tolerance and safety profile. Moclobemide has little effect on psychomotor functions. Other side effects include nausea, insomnia, tremor and lightheadedness; orthostatic hypotension (dizziness upon standing) is uncommon even among the elderly. Behavioural toxicity or other impairments relating to everyday living does not occur with moclobemide, except that in doses of 400 mg or higher peripheral reaction time may be impaired. Peripheral oedema has been associated with moclobemide.
Some of the side effects are transient and disappear within 2 weeks of treatment. Serious fatigue, headache, restlessness, nervousness and sleep disturbances have been described as side effects from moclobemide therapy. A paradoxical worsening of depression has been reported in some individuals in several studies, and reports of suicide or suicidal ideation have been reported as a rare adverse effect of moclobemide. Overall, antidepressants decrease the risk of suicide. Moclobemide is believed to have only small proconvulsant effects; however, rarely seizures may occur. Hypertension has been reported to occur very rarely with moclobemide therapy.
Moclobemide is relatively well tolerated. The following are the potential adverse effects and their respective incidences:

Common (>1% incidence) adverse effects
Nausea
Dry mouth
Constipation
Diarrhea
Insomnia
Dizziness
Anxiety
Restlessness
Uncommon/Rare (<1%) adverse effects

### Tolerance and withdrawal

Withdrawal symptoms appear to be very rare with moclobemide compared to other antidepressants; a single report of relatively mild flu-like symptoms persisting for 7 days after rapid reduction of high dose moclobemide therapy has been reported in one patient. Withdrawal of moclobemide causes a rebound in REM sleep.
Moclobemide does not seem to prevent withdrawal symptoms from serotonin reuptake inhibitors.
Discontinuation of moclobemide is recommended to be done gradually to minimise side effects (e.g. rapid return of condition being treated and/or the appearance of withdrawal symptoms). Tolerance to the therapeutic effects has been reported in a small number of users of MAOIs including moclobemide.

## Overdose

Moclobemide is considered to be less toxic in overdose compared to older antidepressants, such as the tricyclic antidepressants and the irreversible and non-selective MAOIs, making it a safer antidepressant in the elderly or people with physical disorders. Of 18 people who overdosed on moclobemide during clinical trials, all recovered fully and moclobemide was judged to be safe for inpatient as well as outpatient use. Intoxications with moclobemide as single agent are usually mild; however, when combined with tricyclic or SSRI antidepressants the overdose is much more toxic and potentially fatal. Moclobemide, is preferred by doctors for patients who are at risk of suicide, due to moclobemide's low toxicity in overdose. Patients with mixed intoxications (e.g. with other CNS active drugs) may show severe or life-threatening symptoms and should be hospitalized. Treatment is largely symptomatic and should be aimed at maintenance of the vital functions.

### Preclinical toxicology

Acute toxicity: The oral LD50 values in mouse and rat are quite high, indicating a wide therapeutic index. LD50 for mice is 730 mg/kg and for rats 1,300 mg/kg. In dogs doses in excess of 300 mg/kg led to vomiting, salivation, ataxia, and drowsiness.
Chronic toxicity: In an 18-months-study in rats with 10 mg/kg no signs of chronic toxicity were noted, with 50 mg/kg and 250 mg/kg only a slight loss of weight, and with 250 mg/kg mildly elevated Alkaline phosphatase and Gamma-GT. Studies in dogs revealed no toxicity relevant for humans. No evidence for a possible hepatic or cardiovascular toxicity was found.

## Interactions

Moclobemide has fewer interactions than irreversible MAOIs. Cimetidine however, causes a significant rise in moclobemide levels and therefore if the combination is used, lower doses of moclobemide have been recommended. There is little increase in the effects of alcohol when combined with moclobemide and, in fact, moclobemide causes a reduction in alcohol-related impairments. Moclobemide also interacts with pethidine/meperidine, and dextropropoxyphene. Ephedrine in combination with moclobemide increases the risk of cardiovascular adverse effects. Moclobemide is also likely to interact with warfarin.
The combination of moclobemide with prescription or over the counter sympathomimetic drugs is not recommended due to the potential of significant drug interactions.
Serotonin syndrome has been reported when moclobemide has been taken in combination with other serotonin enhancing drugs; however, due to moclobemide's reversible MAO inhibition, serotonin syndrome is significantly less likely to occur with moclobemide than with older irreversible MAOIs. Serotonin syndrome has been reported when trazodone was abruptly replaced with moclobemide. Taking at the same time or starting moclobemide too soon after discontinuing clomipramine or serotonin reuptake inhibitors such as SSRIs may result in the development of a serotonin syndrome. SNRIs such as venlafaxine in combination with moclobemide have also been associated with serotonin syndrome. Cimetidine causes a doubling of the blood plasma levels of moclobemide. Blood plasma levels of trimipramine and maprotiline and possibly other tricyclic antidepressants increase when used in combination with moclobemide and may require dosage adjustments if the combination is used for treatment resistant depression. The elimination of zolmitriptan is reduced by moclobemide and if the combination is used, a dose reduction of zolmitriptan is recommended. Moclobemide reduces the metabolism of dextromethorphan. Moclobemide may decrease metabolism of diazepam, omeprazole, proguanil, propranolol and others due to inhibition of CYP2C19.

### Dietary interactions

Irreversible MAOIs can cause unpleasant and occasionally dangerous side effects such as a hypertensive crises after intake of food or drink containing indirectly acting sympathomimetic amines such as tyramine. This is sometimes referred to as the 'cheese effect'. These side effects are due to irreversible inhibition of MAO in the gut and vasomotor neurons. However, the reversible MAOI antidepressants such as moclobemide have a very different side effect profile in this regard. The reversible binding to MAO-A by moclobemide allows amines such as tyramine to displace moclobemide from MAO-A allowing its metabolism and removing the risk of a hypertensive crisis that occurs with irreversible MAO inhibition. Of 2300 people in multiple clinical trials who were treated with moclobemide in doses up to 600 mg with no dietary restrictions, none experienced a tyramine-mediated hypertensive reaction. As the pressor effect of moclobemide is so low, dietary restrictions are not necessary in people eating a normal diet, in contrast to irreversible MAOIs. However, some rare cheeses that have a high tyramine level may possibly cause a pressor effect and require caution. The potentiation of the pressor effect of tyramine by moclobemide is only one seventh to one tenth of that of irreversible MAOIs. In order to minimize this potentiation, postprandial administration (taken after meals) of moclobemide is recommended. The combined use of moclobemide and selegiline requires dietary restrictions as the combination can lead to increased sensitivity to the pressor effect of foods containing tyramine.
While moclobemide or the irreversible MAO-B selective inhibitor selegiline taken alone has very little pressor effect, and requires no dietary restriction, the combination of selegiline with moclobemide leads to a significant enhancement of the pressor effect and such a combination requires dietary restriction of foods containing high amounts of tyramine. The combination of moclobemide and a reversible MAO-B inhibitor requires tyramine dietary restrictions.

## Pharmacology

### Pharmacodynamics

Moclobemide is a benzamide, derivative of morpholine, which acts pharmacologically as a selective, reversible inhibitor of monoamine oxidase-A (RIMA), a type of monoamine oxidase inhibitor (MAOI), and increases levels of norepinephrine (noradrenaline), dopamine, and especially serotonin in neuronal cells as well as in synaptic vesicles; extracellular levels also increase which results in increased monoamine receptor stimulation and suppression of REM sleep, down regulation of beta-3 adrenergic receptors. Moclobemide's primary action is to disable MAO-A enzymes from decomposing norepinephrine, serotonin, and dopamine which results in a rising level of these neurotransmitters. Although it has been estimated that a single 300 mg dose of moclobemide inhibits 80% of monoamine oxidase-A (MAO-A) and 20-30% of MAO-B, studies evaluating brain occupancy of MAO-A enzymes have shown dosages of 600 mg to only inhibit 74% of MAO-A enzymes and dosages in the 900–1200 mg range to inhibit slightly less MAO-A than phenelzine (Nardil) at 45–60 mg; subsequently, it is highly plausible that reports of lower efficacy could be largely or entirely the consequence of conservative dosage guidelines rather than the pharmacological properties of the drug. Previously, it was widely reported that both MAO-A and MAO-B enzymes were responsible for the metabolism of dopamine; however, new research suggests that MAO-B enzymes are involved in the generation of GABA and not the degradation of dopamine. There is also some evidence of moclobemide possessing neuroprotective properties in rodent models. There is no cumulative effect of moclobemide centrally when taken long-term. With long-term use of moclobemide, there is a significant down-regulation of B-adrenoceptors. Single or repeated dosing with 100–300 mg of moclobemide leads to a reduction in deaminated metabolites of amines such as 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylethylglycol as well as 5-HIAA. Excretion of homovanillic acid and vanillylmandelic acid via urine is also reduced. There is also a temporary increase in prolactin during initial intake of 100–300 mg of moclobemide. L-dihydroxyphenylalanine is also reduced. Inhibition of the serotonin metabolite is less pronounced than the norepinephrine metabolite which suggests there are other major metabolic pathways for serotonin other than MAO-A.
It has been described as a 'slow binding inhibitor', whereby conformational changes to either moclobemide or the enzyme to MAO-A slowly form a more tightly bound complex, resulting in the non-competitive MAO inhibition by moclobemide. With three times daily dosing the inhibition on MAO-A was relatively constant with moclobemide. The MAO inhibition of moclobemide lasts about 8–10 hours and wears off completely by 24 hours after dosing. The inhibition of MAO-A by moclobemide is 10 times more potent than the irreversible MAOI phenelzine and approximately equivalent to tranylcypromine and isocarboxazid.
Moclobemide increases levels of extracellular monoamines and decreases levels of their metabolites in rat brains; tolerance to these effects does not seem to occur with chronic use of moclobemide. Moclobemide lacks anticholinergic effects and cognitive impairments can be improved by moclobemide. Moclobemide suppresses the unstimulated release of certain proinflammatory cytokines which are believed to be involved in the pathophysiology of major depression and stimulates the release of anti-inflammatory cytokines. Long-term treatment with moclobemide leads to an increase in cyclic adenosine monophosphate (cAMP) binding to cAMP-dependent protein kinase (PKA).
Moclobemide is chemically unrelated to irreversible MAOI antidepressants and only has a very weak pressor effect of orally administered tyramine. In humans, the n-oxide metabolites of moclobemide and moclobemide itself are the compounds that produce most of the inhibition of MAO-A; other metabolites are significantly less potent than the parent compound.
In healthy people moclobemide has a relatively small suppressing effect on REM sleep; in contrast, depressed people who have been treated with moclobemide, progressively show improved sleep over a 4-week period, with an increase in stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. There have been conflicting findings with regard to moclobemide altering cortisol levels and whether moclobemide increases growth hormone levels. Testosterone levels increase significantly with long-term use of moclobemide in depressed males.
Moclobemide also has neuroprotective properties in its demonstrated anti-hypoxia or anti-ischemia effects; there is a possibility that moclobemide may possess similar neuro-rescuing properties, similar to selegiline, however, research is required to determine this. Moclobemide has also been demonstrated in a single dose research study to possess antinociceptive properties.
Platelet MAO is of the MAO-B and this is inhibited only to a small degree in humans; the inhibition is due to low levels of metabolites of moclobemide that have MAO-B inhibiting properties. Moclobemide has been reported to be a mixed MAO-A/MAO-B inhibitor in rats but in man, it has been reported to be a pure MAO-A inhibitor, blocking the decomposition of norepinephrine, serotonin and, to a lesser extent, dopamine. No reuptake inhibition of any of the neurotransmitters occurs. The pharmacodynamic action encompasses activation, elevation of mood, and improvement of symptoms like dysphoria, fatigue, and difficulties in concentration. The duration and quality of sleep may be improved. In the treatment of depression the antidepressant effect often becomes evident in the first week of therapy (earlier than typically noted with TCAs/SSRIs).
MAO activity returns completely back to normal after 24 hours of the last dose, which allows for a quick switch to another antidepressant after the 24 hours.

### Pharmacokinetics

In humans moclobemide is rapidly and almost completely absorbed and totally metabolised via the liver. Peak plasma levels occur 0.3 to 2 hours after oral administration. The bioavailability increases during the first week of therapy from 60% to 80% and more. The elimination half-life is around 2 hours. It is moderately bound to plasma proteins, especially albumin. However, the short disposition half-life somewhat increases after repeated dosing; moclobemide has an intermediate elimination half-life for systemic clearance and an intermediate volume of distribution. Despite its short half-life the pharmacodynamic action of a single dose persists for approximately 16 hours. The drug is almost completely metabolized in the liver; it is a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2. Less than 1 percent of the drug is excreted unchanged; 92 percent of the metabolised drug is excreted within the first 12 hours. The main metabolites are the N-oxide Ro 12-5637 formed via morpholine N-oxidation and lactam derivative Ro 12-8095 formed via morpholine C-oxidation; active metabolites are found only in trace amounts. The unchanged drug (less than 1%) as well as the metabolites are excreted renally (in urine). The main degradation pathway of moclobemide is oxidation. About 44 percent of the drug is lost due to the first pass effect through the liver. Age and renal function do not affect the pharmacokinetics of moclobemide. However, patients with significantly reduced liver function require dose reductions due to the significant slowing of metabolism of moclobemide. Food slows the absorption but does not affect the bioavailability of moclobemide.
Steady state concentrations are established after one week. It has been suggested that changes in dose should not be made with a gap of less than a week. Moclobemide has good penetration across the blood brain barrier with peak plasma levels within the central nervous system occurring 2 hours after administration.

## History

Irreversible MAOI antidepressants were discovered accidentally in the 1950s but their popularity declined as their toxicity especially their dangerous food interactions became apparent and rival tricyclic antidepressants were discovered. Reversible MAOIs were developed in the hope that they would exert efficacy in depressive disorders but with less of the toxicity of the older irreversible compounds; moclobemide's discovery and marketing brought the renewed interest in MAOIs due to an absence of dangerous tyramine food interactions and potent antidepressant effects. In 1992 moclobemide was launched onto the world markets. Moclobemide was the first reversible MAO-A inhibitor to be widely marketed. Moclobemide as well as other newer antidepressants such as the SSRIs led to changes in prescribing patterns and broadened the treatment options for the management of depressive disorders.
When moclobemide was discovered in 1972 in Switzerland, it was first hypothesized as being an antilipaemic or antibiotic, but the screenings were negative. The search for its antidepressant qualities, based on anticholinergic tests, also proved negative and moclobemide was then suspected of being an antipsychotic before its specific and reversible MAO-A inhibition qualities were detected. After the establishment of its lack of relevant interference with tyramine pressure response, clinical trials were launched in 1977 and further trials confirmed the broad antidepressant activity of RIMAs. It was first approved in Sweden in 1989 and then the United Kingdom and Europe as the first reversible and selective inhibitor of MAO-A and is now approved in over 50 countries worldwide. The Australian TGA approved moclobemide in December 2000. Subsequent research found that moclobemide is well tolerated in elderly patients and far superior to tricyclic antidepressants in terms of side effects, tolerability and overdose. With regard to effectiveness in the treatment of depression, moclobemide was determined to be as effective as all major antidepressant drug classes. There is no need for dietary restrictions in contrast to people on irreversible MAOIs and apart from an important interaction with other serotonergic enhancing agents such as SSRIs and pethidine, there are few serious drug interactions and because of these benefits, moclobemide became regarded as a beneficial addition to medical 'prescribing arsenal'. Additionally moclobemide was found, unlike most other antidepressants on the market, to actually improve all aspects of sexual function. It is the only reversible MAOI in use in clinical practice. The fact that moclobemide's pharmacokinetic properties are unaltered by age, that cognition is improved in the elderly, and moclobemide has low potential for food and drug interactions opened up a new avenue for the treatment of major depressive disorder. Due to a lack of financial incentive, such as the costs of conducting the necessary trials to gain approval, moclobemide is unavailable in the US pharmaceutical market. In 2016 moclobemide was discontinued in Brazil for commercial reasons.

## Society and culture

### Brand names

It is sold under many trade names worldwide. These include Apo-Moclob, Apo-Moclobemide, Auromid, Aurorix, Bei Su, Biorix, Depnil, Eutac, Hai Bei Lin, Langtian, Manerix, Mobemid, Moclamine, Moclo A, Moclobemid - 1 A Pharma, Moclobemid AL, Moclobemid HEXAL, Moclobemid ratiopharm, Moclobemida, Moclobemida Genedec, Moclobemida Teva, Moclobemide Actavis, Moclobemide Aurobindo, Moclobemide CF, Moclobemide Mylan, Moclobemide Sandoz, Moclobemide Sopharma, Moclobemide Teva, Moclobemid-neuraxpharm, Moclobemid-ratiopharm, Moclobeta, Moclod, moclodura, Moclostad, Mocrim, Moklar, Teva-Moclobemide, Tian Tai, Ya Zheng, and Zorix.
`,
};
